ADL Amdl,

TUSTIN, Calif., June 25 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company that engages in the development, manufacture and marketing of proprietary pharmaceutical and diagnostic products. AMDL announced today that through its subsidiary, JJB, it has signed an agreement with YunNan KunMing YuSi Pharmaceutical Co. Ltd. (YKY) to distribute levofloxacin (100ml/bottle). This $921,000 distribution agreement will be effective in July 2007 for a term of two years. YKY is a direct affiliate to the Commission of Science Technology and Industry for National Defense. Mr. Frank Zheng, Managing Director of JPI, stated that "this additional purchase orders puts JPI on its way to building sales in China by as much as $24 million over the next 12 month sales cycle." Mr. Gary Dreher, CEO of AMDL, noted that "this additional purchase agreement is truly exciting and significantly enhances JPI's ability to grow its sales in the China markets." About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiary, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards. About AMDL: More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements: This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul Knopick, AMDL Investor Relations, +1-949-707-5365, voice mail, +1-714-505-4460 Web site: http://www.amdl.com/

Copyright